4,6-Dichloro-2-Methylpyrimidine CAS 1780-26-3 Puritas ≥99.5% (GC) Factory Hot Sale
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of 4,6-Dichloro-2-Methylpyrimidine (CAS: 1780-26-3) with high quality, commercial production. We can provide COA, worldwide delivery, small and bulk quantities available. Please contact: alvin@ruifuchem.com
Nomen chemicum | 4,6-Dichloro-2-Methylpyrimidine |
Synonyma | 2-Methyl-4,6-Dichloropyrimidines;2,4-Dichloro-6-Methylpyrimidine |
CAS Number | 1780-26-3 |
CATTUS Number | RF-PI687 |
Stock Status | In Stock, Productio Ascendite ad Tons |
Formulae hypotheticae | C5H4Cl2N2 |
M. Pondus | 163.00 |
Liquescens punctum | 41.5~45.5' (lit.) |
Solubilitas (Solubile in) | Methanol |
Brand | Ruifu Chemical |
Item | Specifications |
Aspectus | Alba vel Off-White Crystalline pulveris |
Puritas / Analysis Methodus | ≥99.5% (GC) |
Damnum in Siccatio | ≤0.50% |
Residere in Ignition | ≤0.20% |
una immunditia | ≤0.50% |
Totalis immunditias | ≤0.50% |
Test Standard | Enterprise Standard |
Consuetudinem | Pharmaceutical Medium;Dasatinib/Moxonidine Intermediate |
4,6-Dichloro-2-Methylpyrimidines (CAS: 1780-26-3) Processus Route
sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore
4,6-Dichloro-2-Methylpyrimidines (CAS: 1780-26-3) adhibetur in synthesi intermediorum pharmaceuticorum et APIs.Praeparatio Products: Moxonidine (CAS: 75438-57-2);Dasatinib (CAS: 302962-49-8);Dasatinib Monohydratorum (CAS: 863127-77-9);4-Chloro-2,6-Dimethylpyrimidine (CAS: 4472-45-1);4-Amino-6-Chloro-2-Methylpyrimidine (CAS: 1749-68-4).Moxonidine est novum genus medicamentorum antihypertensivum, communiter in curatione hypertensionis essentialis.Comparatus cum antihypertensivis antihypertensivis centrali vetustioribus, Moxonidine ligat multo maiore affinitate cum imidazolino I1-receptori quam cum α2-receptatore.Dasatinib est inhibitor kinasus oncogenicus oralis potens, qui signum replicationis accelerationis cellae cancri obstruere potest, mense Maio 2009, US Cibus et Administration medicamentis (FDA) venditionem dasatinib formaliter approbavit , amet adhibitum est ad tractationem diversorum chronicorum. myeloid leukemia (CML), inter curationem myeloidalis longi leukemia quae resistit vel intolerans programmata tractandi possidet mesylata imatinib., Philadelphia chromosoma-positiva acuta leukemia lymphoblastica (Ph + ALL) et curatio aegrorum cum solidis tumoribus.